US12655203B2 - Neutralizing antibody for tooth regeneration treatment targeting USAG-1 molecule - Google Patents

Neutralizing antibody for tooth regeneration treatment targeting USAG-1 molecule

Info

Publication number
US12655203B2
US12655203B2 US17/625,520 US202017625520A US12655203B2 US 12655203 B2 US12655203 B2 US 12655203B2 US 202017625520 A US202017625520 A US 202017625520A US 12655203 B2 US12655203 B2 US 12655203B2
Authority
US
United States
Prior art keywords
seq
amino acid
antibody
set forth
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active, expires
Application number
US17/625,520
Other languages
English (en)
Other versions
US20220259298A1 (en
Inventor
Katsu Takahashi
Manabu Sugai
Yoshihito Tokita
Junichi Takagi
Emiko MIHARA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Fukui
Kyoto University
The University of Osaka
Original Assignee
Osaka University NUC
University of Fukui
Kyoto University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osaka University NUC, University of Fukui, Kyoto University filed Critical Osaka University NUC
Assigned to AICHI PREFECTURE reassignment AICHI PREFECTURE ASSIGNMENT OF ASSIGNOR'S INTEREST Assignors: TOKITA, Yoshihito
Assigned to KYOTO UNIVERSITY reassignment KYOTO UNIVERSITY ASSIGNMENT OF ASSIGNOR'S INTEREST Assignors: TAKAHASHI, Katsu
Assigned to AICHI PREFECTURE reassignment AICHI PREFECTURE ASSIGNMENT OF ASSIGNOR'S INTEREST Assignors: TOKITA, Yoshihito
Assigned to UNIVERSITY OF FUKUI reassignment UNIVERSITY OF FUKUI ASSIGNMENT OF ASSIGNOR'S INTEREST Assignors: SUGAI, MANABU
Assigned to OSAKA UNIVERSITY reassignment OSAKA UNIVERSITY ASSIGNMENT OF ASSIGNOR'S INTEREST Assignors: MIHARA, Emiko, TAKAGI, JUNICHI
Assigned to KYOTO UNIVERSITY reassignment KYOTO UNIVERSITY ASSIGNMENT OF ASSIGNOR'S INTEREST Assignors: AICHI PREFECTURE
Publication of US20220259298A1 publication Critical patent/US20220259298A1/en
Application granted granted Critical
Publication of US12655203B2 publication Critical patent/US12655203B2/en
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Materials For Medical Uses (AREA)
US17/625,520 2019-07-12 2020-07-10 Neutralizing antibody for tooth regeneration treatment targeting USAG-1 molecule Active 2043-06-11 US12655203B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2019130153 2019-07-12
JP2019-130153 2019-07-12
JP2020-080723 2020-04-30
JP2020080723 2020-04-30
PCT/JP2020/027127 WO2021010346A1 (ja) 2019-07-12 2020-07-10 歯の再生治療のためのｕｓａｇ－１を標的分子とした中和抗体

Publications (2)

Publication Number Publication Date
US20220259298A1 US20220259298A1 (en) 2022-08-18
US12655203B2 true US12655203B2 (en) 2026-06-16

Family

ID=74209883

Family Applications (1)

Application Number Title Priority Date Filing Date
US17/625,520 Active 2043-06-11 US12655203B2 (en) 2019-07-12 2020-07-10 Neutralizing antibody for tooth regeneration treatment targeting USAG-1 molecule

Country Status (6)

Country Link
US (1) US12655203B2 (cg-RX-API-DMAC10.html)
EP (1) EP4000633A4 (cg-RX-API-DMAC10.html)
JP (3) JP7572668B2 (cg-RX-API-DMAC10.html)
KR (1) KR20220034176A (cg-RX-API-DMAC10.html)
CN (2) CN118307669A (cg-RX-API-DMAC10.html)
WO (1) WO2021010346A1 (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7572668B2 (ja) 2019-07-12 2024-10-24 国立大学法人京都大学 歯の再生治療のためのｕｓａｇ－１を標的分子とした中和抗体
US20240043841A1 (en) * 2020-02-21 2024-02-08 Kyoto University Medicine Containing USAG-1-Targeting RNA Molecule for Tooth Regeneration Therapy
JPWO2023148894A1 (cg-RX-API-DMAC10.html) * 2022-02-03 2023-08-10
CN116425870B (zh) * 2023-05-24 2026-05-22 陕西师范大学 一种抗新型冠状病毒n蛋白单克隆抗体31a8及其产品和应用

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003106657A2 (en) 2002-06-14 2003-12-24 Stowers Institute For Medical Research Wise/sost nucleic acid sequences and amino acid sequences
US20090130114A1 (en) 2007-11-21 2009-05-21 Xueming Qian Wise binding agents and epitopes
US20090130113A1 (en) 2007-10-12 2009-05-21 Michaela Kneissel Compositions and methods for use for antibodies against sclerostin
US20120101005A1 (en) 2009-06-26 2012-04-26 Ge Healthcare Uk Limited Methods for predicting the toxicity of a chemical
US20130195856A1 (en) 2006-12-29 2013-08-01 Ossifi Inc. Methods of altering bone growth by administration of sost or wise antagonist or agonist
WO2018027039A1 (en) 2016-08-03 2018-02-08 Nextcure, Inc. Compositions and methods for modulating lair signal transduction
WO2021010346A1 (ja) 2019-07-12 2021-01-21 国立大学法人京都大学 歯の再生治療のためのｕｓａｇ－１を標的分子とした中和抗体
US11485787B2 (en) * 2014-02-05 2022-11-01 Dana-Farber Cancer Institute, Inc. Agents that modulate RGMb-neogenin-BMP signaling and methods of use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8176798A (en) * 1997-06-30 1999-01-19 Genetics Institute Inc. Secreted proteins
CN1618807A (zh) * 2003-11-21 2005-05-25 上海人类基因组研究中心 分泌蛋白及其编码序列和用途
AU2005256113B2 (en) * 2004-07-09 2011-02-10 Chugai Seiyaku Kabushiki Kaisha Anti-glypican 3 antibody
US20120288507A1 (en) * 2009-12-18 2012-11-15 Amgen Inc. Wise binding agents and epitopes
PT2832365T (pt) * 2012-03-30 2018-01-24 Toray Industries Composição farmacêutica para o tratamento e/ou prevenção do cancro hepático
EP3365369A1 (en) * 2015-10-23 2018-08-29 Pfizer Inc Anti-il-2 antibodies and compositions and uses thereof

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003106657A2 (en) 2002-06-14 2003-12-24 Stowers Institute For Medical Research Wise/sost nucleic acid sequences and amino acid sequences
WO2003106657A3 (en) 2002-06-14 2005-09-15 Stowers Inst For Medical Res Wise/sost nucleic acid sequences and amino acid sequences
US20130195856A1 (en) 2006-12-29 2013-08-01 Ossifi Inc. Methods of altering bone growth by administration of sost or wise antagonist or agonist
US20090130113A1 (en) 2007-10-12 2009-05-21 Michaela Kneissel Compositions and methods for use for antibodies against sclerostin
JP2016121170A (ja) 2007-10-12 2016-07-07 メレオ バイオファーマ ３ リミテッド スクレロスチンに対する抗体の使用のための組成物および方法
US20090130114A1 (en) 2007-11-21 2009-05-21 Xueming Qian Wise binding agents and epitopes
JP2014167002A (ja) 2007-11-21 2014-09-11 Amgen Ｗｉｓｅ結合抗体及びエピトープ
US20120101005A1 (en) 2009-06-26 2012-04-26 Ge Healthcare Uk Limited Methods for predicting the toxicity of a chemical
JP2012530502A (ja) 2009-06-26 2012-12-06 ジーイー・ヘルスケア・ユーケイ・リミテッド 化学物質の毒性を予測する方法
US11485787B2 (en) * 2014-02-05 2022-11-01 Dana-Farber Cancer Institute, Inc. Agents that modulate RGMb-neogenin-BMP signaling and methods of use thereof
WO2018027039A1 (en) 2016-08-03 2018-02-08 Nextcure, Inc. Compositions and methods for modulating lair signal transduction
WO2018027039A8 (en) 2016-08-03 2019-03-07 Nextcure, Inc. COMPOSITIONS AND METHODS FOR MODULATING LAIR SIGNAL TRANSDUCTION
WO2021010346A1 (ja) 2019-07-12 2021-01-21 国立大学法人京都大学 歯の再生治療のためのｕｓａｇ－１を標的分子とした中和抗体
JP2021176829A (ja) 2019-07-12 2021-11-11 国立大学法人京都大学 歯の再生治療のためのｕｓａｇ−１を標的分子とした中和抗体
US20220259298A1 (en) 2019-07-12 2022-08-18 Kyoto University Neutralizing Antibody for Tooth Regeneration Treatment Targeting USAG-1 Molecule

Non-Patent Citations (48)

* Cited by examiner, † Cited by third party
Title
Abitbol et al., "Sostdc1, a secreted dual BMP and WNT antagonist is differentially expressed in RCS rdy+ and rdy− rat retinal pigment epithelial cells," ARVO Annual Meeting Abstract, 58 (610) (Jun. 2017).
Casset et al. (Biochemical and Biophysical Research Communications, 2003, 307:198-205) (Year: 2003). *
Chen et al. (Journal of Molecular Biology, 1999, 293:865-881) (Year: 1999). *
Chen et al., "Mesenchymal Wnt-beta-catenin signaling induces Wnt and BMP antagonists in dental epithelium," Organogenesis, 15 (2):55-67 (2019).
Cho et al., "Interactions between Shh Sostdc1 and Wnt signaling and a new feedback loop for spatial patterning of the teeth," Development, 138: 1807-1816 (2011).
De la Lastra et al., "Epitope mapping of 10 monoclonal antibodies against the pig analogue of human membrane cofactor protein (MCP)," Immunology, 96 (4): 663-670 (1999).
Holm et al. (Molecular Immunology, 2007:1075-1084) (Year: 2007). *
International Preliminary Report on Patentability and Written Opinion issued in related International Patent Application No. PCT/JP2022/004300 dated Aug. 15, 2024.
International Preliminary Report on Patentability issued in corresponding International Patent Application No. PCT/JP2020/027127 dated Jan. 27, 2022.
International Search Report issued in corresponding International Patent Application No. PCT/JP2020/027127 dated Sep. 24, 2020.
International Search Report issued in related International Patent Application No. PCT/JP2022/004300 dated Apr. 26, 2022.
MacCallum et al. (Journal of Molecular Biology, 1996, 262:732-745) (Year: 1996). *
Nakao et al., "The development of a bioengineered organ germ method," Nature Methods, 4 (3): 227-230 (2007).
Office Action dated Jun. 4, 2024, issued in corresponding Japanese Patent Application No. 2020-119469.
Office Action issued in corresponding Japanese Patent Application No. 2023-578282, dated Dec. 23, 2025.
Office Action issued in corresponding Korean Patent Application No. 10-2022-7004179, dated Dec. 16, 2025.
Office Action issued in Indian Patent Application No. 202447063666, dated Apr. 6, 2026.
Office Action, including search report, issued in related Chinese Patent Application No. 202080063186.9 dated Aug. 25, 2023.
Ohazama et al., "Stem-cell-based Tissue Engineering of Murine Teeth," Journal of Dental Research, 83(7): 518-522 (2004).
Partial Supplementary European Search Report issued in corresponding European Patent Application No. 20840397.2 dated Oct. 20, 2023.
Rudikoff et al. (Proceedings of the National Academy of Sciences, 1982, 79:1979-1983) (Year: 1982). *
Rudikoff et al., "Single amino acid substitution altering antigen-binding specificity," PNAS, 79: 1979-1983 (1982).
Supplementary European Search Report dated Jan. 23, 2024, issued in corresponding European Patent Application No. 20840397.2.
Yanagita, "Balance between bone morphogenetic proteins and their antagonists in kidney injury," THerapeutic Apheresis and Dialysis 11 (Supplement 1): S38-S43 (2007).
Abitbol et al., "Sostdc1, a secreted dual BMP and WNT antagonist is differentially expressed in RCS rdy+ and rdy− rat retinal pigment epithelial cells," ARVO Annual Meeting Abstract, 58 (610) (Jun. 2017).
Casset et al. (Biochemical and Biophysical Research Communications, 2003, 307:198-205) (Year: 2003). *
Chen et al. (Journal of Molecular Biology, 1999, 293:865-881) (Year: 1999). *
Chen et al., "Mesenchymal Wnt-beta-catenin signaling induces Wnt and BMP antagonists in dental epithelium," Organogenesis, 15 (2):55-67 (2019).
Cho et al., "Interactions between Shh Sostdc1 and Wnt signaling and a new feedback loop for spatial patterning of the teeth," Development, 138: 1807-1816 (2011).
De la Lastra et al., "Epitope mapping of 10 monoclonal antibodies against the pig analogue of human membrane cofactor protein (MCP)," Immunology, 96 (4): 663-670 (1999).
Holm et al. (Molecular Immunology, 2007:1075-1084) (Year: 2007). *
International Preliminary Report on Patentability and Written Opinion issued in related International Patent Application No. PCT/JP2022/004300 dated Aug. 15, 2024.
International Preliminary Report on Patentability issued in corresponding International Patent Application No. PCT/JP2020/027127 dated Jan. 27, 2022.
International Search Report issued in corresponding International Patent Application No. PCT/JP2020/027127 dated Sep. 24, 2020.
International Search Report issued in related International Patent Application No. PCT/JP2022/004300 dated Apr. 26, 2022.
MacCallum et al. (Journal of Molecular Biology, 1996, 262:732-745) (Year: 1996). *
Nakao et al., "The development of a bioengineered organ germ method," Nature Methods, 4 (3): 227-230 (2007).
Office Action dated Jun. 4, 2024, issued in corresponding Japanese Patent Application No. 2020-119469.
Office Action issued in corresponding Japanese Patent Application No. 2023-578282, dated Dec. 23, 2025.
Office Action issued in corresponding Korean Patent Application No. 10-2022-7004179, dated Dec. 16, 2025.
Office Action issued in Indian Patent Application No. 202447063666, dated Apr. 6, 2026.
Office Action, including search report, issued in related Chinese Patent Application No. 202080063186.9 dated Aug. 25, 2023.
Ohazama et al., "Stem-cell-based Tissue Engineering of Murine Teeth," Journal of Dental Research, 83(7): 518-522 (2004).
Partial Supplementary European Search Report issued in corresponding European Patent Application No. 20840397.2 dated Oct. 20, 2023.
Rudikoff et al. (Proceedings of the National Academy of Sciences, 1982, 79:1979-1983) (Year: 1982). *
Rudikoff et al., "Single amino acid substitution altering antigen-binding specificity," PNAS, 79: 1979-1983 (1982).
Supplementary European Search Report dated Jan. 23, 2024, issued in corresponding European Patent Application No. 20840397.2.
Yanagita, "Balance between bone morphogenetic proteins and their antagonists in kidney injury," THerapeutic Apheresis and Dialysis 11 (Supplement 1): S38-S43 (2007).

Also Published As

Publication number Publication date
JP7572668B2 (ja) 2024-10-24
JP2026081263A (ja) 2026-05-18
US20220259298A1 (en) 2022-08-18
EP4000633A4 (en) 2024-02-21
KR20220034176A (ko) 2022-03-17
CN114364694B (zh) 2024-05-10
JP2021176829A (ja) 2021-11-11
WO2021010346A1 (ja) 2021-01-21
JP2025004094A (ja) 2025-01-14
CN114364694A (zh) 2022-04-15
CN118307669A (zh) 2024-07-09
EP4000633A1 (en) 2022-05-25

Legal Events

Date Code Title Description
FEPP Fee payment procedure

Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

FEPP Fee payment procedure

Free format text: ENTITY STATUS SET TO SMALL (ORIGINAL EVENT CODE: SMAL); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

AS Assignment

Owner name: AICHI PREFECTURE, JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:TOKITA, YOSHIHITO;REEL/FRAME:060285/0411

Effective date: 20220511

Owner name: KYOTO UNIVERSITY, JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:TAKAHASHI, KATSU;REEL/FRAME:060285/0401

Effective date: 20220414

Owner name: AICHI PREFECTURE, JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:TOKITA, YOSHIHITO;REEL/FRAME:060285/0399

Effective date: 20220511

Owner name: UNIVERSITY OF FUKUI, JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SUGAI, MANABU;REEL/FRAME:060285/0397

Effective date: 20220413

Owner name: OSAKA UNIVERSITY, JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:TAKAGI, JUNICHI;MIHARA, EMIKO;REEL/FRAME:060285/0395

Effective date: 20220411

AS Assignment

Owner name: KYOTO UNIVERSITY, JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:AICHI PREFECTURE;REEL/FRAME:060717/0551

Effective date: 20220513

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: ALLOWED -- NOTICE OF ALLOWANCE NOT YET MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS

STPP Information on status: patent application and granting procedure in general

Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS

STPP Information on status: patent application and granting procedure in general

Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS

STPP Information on status: patent application and granting procedure in general

Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT RECEIVED

Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT VERIFIED

STCF Information on status: patent grant

Free format text: PATENTED CASE